Searched for
ABBVIE DEAL
US stocks: S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on IranUS market saw a mixed close as the S&P 500 and Nasdaq dipped, primarily due to tech giants like Alphabet facing investor scrutiny over AI s...- US stocks today: S&P 500, Dow tick higher as investors weigh Mideast negotiationsWall Street's major indexes opened little changed on Monday as investors returned from the long holiday weekend and awaited clarity on US-I...
- Micron Technology stock price jumps on Monday, shares up nearly 300 per cent for 2026U.S. Stock Market today: Micron Technology shares moved higher in premarket trading on Monday. AI-driven optimism has supported Wall Stree...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- Merck braces for Keytruda patent loss with $6.7 billion Terns betMerck is acquiring Terns Pharma for $6.7 billion to strengthen its cancer drug pipeline, aiming to reduce reliance on its blockbuster Keytr...
- Eli Lilly bets on next-generation cell therapy with $2.4 billion deal for OrnaEli Lilly will buy Orna Therapeutics for up to $2.4 billion in cash, gaining access to a technology that allows patients' own cells to gen...
- AbbVie in advanced talks to buy cancer drugmaker revolution medicines, shares jump nearly 30%AbbVie is in advanced talks to buy Revolution Medicines, a cancer drug company. The news pushed Revolution Medicines shares sharply higher....
- TrumpRx explained: How Trump’s new drug price deals with 9 pharma companies could save patients moneyTrumpRx: President Donald Trump has struck new deals with nine major drug companies. These agreements aim to reduce prescription drug price...
- US President Donald Trump to announce new deals to lower drug prices, White House saysPresident Trump is set to announce new agreements Friday aimed at lowering prescription drug prices, with major drugmakers like AbbVie, Bri...
- Pharma companies announce direct-to-consumer sales and price cuts in USSeveral drug makers are now selling medicines directly to Americans. This move follows President Trump's push to reduce prescription drug p...
- Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&PS&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing agreement with AbbVi...
- Glenmark surges 20% after major drug licensing deal with AbbVieGlenmark Pharmaceuticals shares surged following a significant licensing agreement. Ichnos Glenmark Innovation partnered with AbbVie for a ...
- Glenmark Pharma shares rally 14% on AbbVie boost; analysts hike targets to Rs 2,800Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer drug, ISB 2001...
- Glenmark Pharmaceuticals shares rally up to 20%, mutual funds lead the charge over retail investorsThe shares of Glenmark Pharmaceuticals surged 20% on Friday, July 11, to a day’s high of Rs 2,286 following a landmark $2 billion licensing...
- Motilal Oswal sees 28% upside in Glenmark Pharma, hails $700 mln cancer drug deal as ‘new era’ for innovation playGlenmark Pharma shares: The brokerage noted that the agreement—executed through Glenmark’s subsidiary, Ichnos Glenmark Innovation (IGI)—“va...
- Glenmark, AbbVie ink $700 million drug licensing dealGlenmark Pharmaceuticals has entered into a significant agreement with AbbVie to commercialize its investigational drug, ISB 2001, targetin...
- Natco launches cut price versions of cancer drug ibrutinib in indiaThe patent for the drug is held by Pharmacyclics for three to four more years in India. Pharmacyclics was globally acquired by US giant Abb...
- Lupin developing new products to treat cancer, other diseasesSharing details, Kamboj said the the Mumbai-based company is currently working on developing various products, including two major ones to ...
- Hedge fund revival quickensEvent-driven funds handed investors a return of about 10% last year.
- Abbott to buy Latin American drugmaker CFR in $2.9 billion dealAbbott Lab would acquire Chile's CFR Pharma SA in a two-part, $2.9 bn deal, to double its branded generic drugs portfolio & expand in fast-...
Load More
